Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kineta ( (KANT) ) has shared an update.
On June 30, 2025, TuHURA Biosciences completed the acquisition of Kineta, Inc., adding a Phase 2 ready VISTA inhibiting monoclonal antibody, now called TBS-2025, to its pipeline. This acquisition is expected to enhance TuHURA’s immuno-oncology offerings and potentially improve treatment responses in cancers with acquired resistance to immunotherapy. The merger resulted in Kineta’s common stock being delisted from OTC Markets, and TuHURA plans to initiate a Phase 2 trial for TBS-2025 in the second half of 2025.
Spark’s Take on KANT Stock
According to Spark, TipRanks’ AI Analyst, KANT is a Neutral.
Kineta faces financial challenges and lacks profitability, reflected in a low financial performance score. Technical analysis shows no strong trends, and valuation metrics are unappealing due to negative earnings. The recent merger announcement offers a positive outlook, but overall risks weigh heavily.
To see Spark’s full report on KANT stock, click here.
More about Kineta
TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company focused on developing novel technologies to overcome resistance to cancer immunotherapy. Their lead product, IFx-2.0, is designed to address primary resistance to checkpoint inhibitors.
Average Trading Volume: 17,208
Technical Sentiment Signal: Sell
Current Market Cap: $4.55M
Learn more about KANT stock on TipRanks’ Stock Analysis page.